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Proteolytic cleavage of huntingtin (Htt) is known to be
a key event in the pathogenesis of Huntington’s
disease (HD). Our understanding of proteolytic
processingofHtt has thus far focusedon theprotease
families—caspases and calpains. Identifying critical
proteases involved in Htt proteolysis and toxicity
using an unbiased approach has not been reported.
To accomplish this, we designed a high-throughput
western blot-based screen to examine the generation
of the smallest N-terminal polyglutamine-containing
Htt fragment. We screened 514 siRNAs targeting the
repertoire of human protease genes. This screen
identified 11 proteases that, when inhibited, reduced
Htt fragment accumulation. Three of these belonged
to the matrix metalloproteinase (MMP) family. One
family member, MMP-10, directly cleaves Htt and
prevents cell death when knocked down in striatal
Hdh111Q/111Q cells. Correspondingly, MMPs are acti-
vated in HD mouse models, and loss of function of
Drosophila homologs of MMPs suppresses Htt-
induced neuronal dysfunction in vivo.
INTRODUCTION
Huntington’s disease (HD) is a dominantly inherited neurodegen-
erative disorder that primarily affects neurons in the striatum and
cortex (Albin, 1995; Cudkowicz and Kowall, 1990; Hedreen et al.,
1991). HD is caused by a polyglutamine (polyQ)-encoding CAG
expansion in the gene for the huntingtin protein (Htt) (TheHunting-
ton’s Disease Collaborative Research Group, 1993). Expression
of mutant Htt leads to selective neuronal dysfunction and degen-
eration despite its ubiquitous expression pattern (Bhide et al.,
1996; Gourfinkel-An et al., 1997). Truncated mutant Htt, in
contrast to full-length mutant Htt, induces apoptosis (Martindale
et al., 1998), and mutant N-terminal Htt fragments have been
observed in human HD tissue and presymptomatic HD mouse
models, suggesting that proteolysis is required for disease
progression (Mende-Mueller et al., 2001; Wang et al., 2008;Wellington et al., 2002). Inhibition of mutant Htt cleavage reduces
and in some cases prevents toxicity in vitro and in vivo, indicating
acausative role forHtt proteolysis inHDpathogenesis (Gafni et al.,
2004;Grahametal., 2006;Kimetal., 1999;Wellingtonetal., 2000).
A number of proteases have been shown to cleave mutant Htt.
Caspases and calpains are the most widely studied and cleave
Htt within the N-terminal region between amino acids 469 and
586 (Gafni et al., 2004; Wellington et al., 2000). Recent work
has identified Htt cleavage sites closer to the N terminus,
between amino acids 105 and 167 (Lunkes et al., 2002;
Ratovitski et al., 2007; Tanaka et al., 2006), producing smaller
and potentially more toxic mutant polyQ-containing fragments.
While these studies have suggested that cathepsins and/or
calpains are the proteases responsible for producing these
smaller fragments, the exact cleavage sites and identity of the
proteases involved have not been unequivocally identified
(Kim et al., 2006; Lunkes et al., 2002; Ratovitski et al., 2007).
Historically, Htt was the first neurodegenerative disease
protein identified as a caspase substrate, and our understanding
of proteolytic processing of Htt has thus far focused on the
cysteine protease families of caspases and calpains (Gafni
et al., 2004; Goldberg et al., 1996; Graham et al., 2006; Hermel
et al., 2004; Wellington et al., 1998, 2002; Yanai et al., 2006). In
this study, we used an unbiased approach to identify other
protease families involved in Htt proteolysis and toxicity. From
a drug development perspective, this is a particularly attractive
approach given that there are 514 known and predicted protease
genes present in the human genome, and many of these have
existing inhibitory compounds developed as therapeutics for
a number of human diseases. One such class of proteases, the
matrix metalloproteinases (MMPs) is involved in a number of
diverse pathological processes. MMPs are zinc-containing
proteolytic enzymes secreted to degrade extracellular matrix
proteins (Hornebeck and Lafuma, 1991). An imbalance in
MMP/TIMP (tissue inhibitor metalloproteinase) activity is impli-
cated in conditions such as rheumatoid arthritis, kidney disease,
cardiovascular disease, and cancer (Baker et al., 2002;
Konttinen et al., 1999; Ronco et al., 2007). Recent evidence
has linked inhibition of MMPs to reduced neuronal damage after
transient cerebral ischemia (Lee et al., 2009). MMP-3 and
MMP-9 knockout mice have significantly decreased striatal
neuronal cell death after intracerebral hemorrhage (Xue et al.,
2009). Further, intraperitoneal injection of the MMP-3/MMP-9Neuron 67, 199–212, July 29, 2010 ª2010 Elsevier Inc. 199
Figure 1. Western Blot Screen for Protease
siRNAs that Reduce the Abundance of the Htt
55 kDa Fragment
(A) siRNA/DNA cotransfection of cells was done in 96-well
format, and transfected cells were incubated 48 hr before
the addition of epoxomicin to stabilize Htt fragments. Cells
were lysed and crude lysates transferred to SDS-PAGE
loading buffer for subsequent western blot analysis. The
first two columns of each plate contained control transfec-
tions—antibody specificity control, nontargeting (NT)
siRNA/empty vector (gray wells); negative control:, NT
siRNA/Htt 138Q full-length (FL) (lavender wells)—and the
rest of the plate contained an individual protease siRNA
w/Htt138Q FL DNA (green wells).
(B) Each of the rows of the 96-well plate transfections in (A)
were loaded onto a single SDS-PAGE gel and subjected to
western blotting. The antibody 1C2 (MAB1574) detects
two robust nonspecific bands (*) in vector only lanes, while
the remaining bands in Htt138Q FL lanes are either unique
or dramatically enriched. The bands range from the full-
length protein (FL) to the 55 kDa fragment of interest
(arrowhead).
(C) Densitometry spectra of the MMP-10 and NT lanes
from the western blot shown in (B). Each gel was
subjected to densitometric analysis of bands, and the
volume ratio of the 55 kDa to FL was compared to the ratio
in the NT control lane to identify candidate proteases.
See also Figure S1.
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Matrix Metalloproteinases Modify Huntingtininhibitor, SB-3CT, showed a decrease in MMP activity and
infarct size in the ischemic cortex in a mouse model of stroke
(Gu et al., 2005). While the importance of MMPs in disease has
led to the development of a few highly specific MMP inhibitors,
further studies are needed to characterize the contribution of
MMP family members to normal cell function and disease.
Given that smaller Htt fragments generally yield greater
cellular toxicity (Hackam et al., 1998; Martindale et al., 1998),
we designed a high-throughput western blot-based screen to
examine the generation of the smallest N-terminal polyQ-con-
taining fragment from full-length Htt. We screened a set of
514 small interfering RNA (siRNA) pools targeting the repertoire
of all known and predicted protease genes encoded in the
human genome to identify those proteases that when inhibited
reduced Htt proteolysis. Our primary screen identified 41 prote-
ases that alter Htt fragment accumulation, and 11 of these were
confirmed in retesting. Nine of the eleven proteases are ex-
pressed in striatal cells, and their knockdown significantly
reduced Htt-mediated striatal cell death in a secondary cellular
toxicity screen. Furthermore, decreasing the levels of five of
these proteases suppressed mutant Htt induced toxicity in a
Drosophila HD model.
Of the nine proteases validated by the secondary screen, three
are matrix metalloproteinase family members, suggesting that
these enzymes play a role in Htt proteolysis and toxicity. We
demonstrate that MMP-10 directly cleaves Htt and reduces200 Neuron 67, 199–212, July 29, 2010 ª2010 Elsevier Inc.cell death when knocked down in striatal
Hdh111Q/111Q cells. We also find that MMP
activity is significantly elevated in mouse
models of HD and reduced MMP activitysuppresses Htt-induced neuronal dysfunction in Drosophila.
These data show that MMPs affect expanded polyQ-Htt proteol-
ysis and toxicity, suggesting this family of enzymes may be rele-
vant therapeutic targets in the disease.
RESULTS
Identification of Proteases Involved in the Generation
of the Small N-terminal Mutant Htt Fragment
Given that smaller Htt fragments generally yield greater cellular
toxicity (Hackam et al., 1998; Martindale et al., 1998), we de-
signed a high-throughput western blot-based screen to examine
the generation of a small N-terminal polyQ-containing fragment
from full-length Htt in a 96-well format (Figure 1A). As shown in
Figure 1B, this screen allows the analysis of multiple proteolytic
cleavage products generated from full-length mutant Htt. Mutant
Htt and cleavage products were detected with a monoclonal
antibody that recognizes the expanded polyQ stretch in the
N-terminus of Htt (1C2). We focused our analysis on the genera-
tion of the smallest N-terminal polyQ containing Htt fragment
observed, which migrates at 55 kDa (Figure 1B, indicated by
arrowhead). siRNAs directed against all 514 known or predicted
human proteases were screened in duplicate for effects on
proteolysis of expanded full-length Htt in HEK293T cells using
the western blot assay. In this primary screen, 41 initial hits
were identified that reduced the levels of the smallest N-terminal
Table 1. Proteases Whose Knockdown Reduced 55 kDa Htt
Fragment in Primary Western Blot Screen
Gene Symbol GeneID Number Description
CAPN5 726 calpain 5
CAPN7 23473 calpain 7
IMP5 162540 intramembrane protease 5
ITGA2B 3674 integrin, alpha 2b (platelet
glycoprotein IIb of IIb/IIIa
complex, antigen CD41)
KLK10 5655 kallikrein-related peptidase 10
KLK11 11012 kallikrein-related peptidase 11
MMP10 116869 matrix metallopeptidase 10
MMP14 4323 matrix metallopeptidase 14
(membrane-inserted)
MMP23B 8510 matrix metallopeptidase 23B
RNF128 79589 ring finger protein 128
SPC18 23478 SEC11 homolog A (S. cerevisiae)
Figure 2. Secondary Screen of Striatal Cell-Based Toxicity Assay
(A) PolyQ expansion in mouse knockin striatal cells produces robust caspase
activation when compared to wild-type controls. Caspase activity was
measured in striatal Hdh7Q/7Q and Hdh111Q/111Q cells undergoing serum with-
drawal for 24 hr. Fold change in activity normalized to nontargeting siRNA (NT)
in Hdh7Q/7Q or Hdh111Q/111Q cells (ANOVA, n = 5, **p < 0.01 or ***p < 0.005).
(B) siRNAs targeting 9 of the 11 proteases found as hits in the primary screen
result in suppression of caspase activation inHdh111Q/111Q cells. siRNAs to the
indicated protease or a NT siRNA control were electroporated into
Hdh111Q/111Q cells and incubated for 48 hr. Caspase 3/7 activity was then
measured 24 hr after serum withdrawal. Fold change in activity normalized
to NT siRNA in Hdh111Q/111Q, ANOVA analysis, n = 5, *p < 0.05, **p < 0.01,
***p < 0.001.
The error bars represent standard deviation. See also Figure S2.
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Matrix Metalloproteinases Modify HuntingtinHtt fragment (possible aspartyl Htt cleavage product [Lunkes
et al., 2002]) with at least a 30% reduction in expression of the
Htt fragment relative to the full-length protein. This analysis was
done using densitometry as shown in Figure 1C. The conditions
of this assay result in significant knockdown of specific protease
targets as demonstrated by western blot analysis of caspases
(see Figure S1 available online).
Retesting of these 41 primary hits resulted in 11 of the hits
being confirmed by their consistent decrease in the production
of the 55 kDa putative aspartyl Htt cleavage product (Table 1).
The proteases identified include members of the calpain family
(CAPN5 and CAPN7); the signal peptide protease-like IMP5; an
aminoterminal signal peptide protease (SPC18); members of the
secreted serine-protease kallikrein family (KLK10 and KLK11);
the transmembrane-E3-ubiquitin ligase, RNF128; the MMP-2
interacting integrin, ITGA2B (Choi et al., 2008b); and three
members of the matrix metalloproteinase family (MMP-10,
MMP-14, MMP-23B).
Secondary Screen for Modifiers of Htt Toxicity
in Immortalized Mouse Striatal Cells
There is a body of literature suggesting that truncation of the
full-length protein is cytotoxic in all polyQ diseases. For Htt
protein, the smaller N-terminal truncation products are associ-
ated with increased toxicity. Since the 55 kDa product is the
smallest detectable Htt cleavage product in our western blot
analysis, we predict that blocking production of this fragment
will prevent Htt-mediated cell death. To analyze the effect of
the 11 initial hits identified in our western blot screen, we devel-
oped a Htt-mediated cell death assay relevant to HD. Since HD
primarily affects striatal and cortical neurons we used
immortalized mouse striatal cellHdh7Q/7Q andHdh111Q/111Q lines
for our secondary screen of cellular toxicity, as well as subse-
quent genetic and biochemical studies (Trettel et al., 2000).
Previous work in our laboratory has demonstrated that striatal
cells from mutant Htt knockin mice have altered calcium
handling (Oliveira et al., 2006) and other groups have reportedthat they are selectively vulnerable to mitochondrial complex II
inhibitor-induced cell death through a non-apoptotic pathway
(Mao et al., 2006; Milakovic and Johnson, 2005). To develop
an assay relevant to cell death, we cultured Hdh7Q/7Q and
Hdh111Q/111Q cells and measured caspase activation 24 hr after
serum withdrawal (Figure 2A). We found that Hdh111Q/111Q cells
have a 3.7-fold increase in caspase activation compared to
control Hdh7Q/7Q. Further, siRNA against caspase-3, which
serves as a positive control in our assay, reduced caspase
activity by 8.7 fold in Hdh111Q/111Q cells (Figure 2A).
Having established a robust striatal cellular toxicity assay, we
evaluated whether the 11 proteases identified in our primary
screen are active in this assay. Intriguingly, siRNA-mediated
knockdown of 9 of the 11 proteases results in significant
reduction of toxicity in this cell model (Figure 2B). KLK10 and
KLK11, the two original hits that were negative in this secondaryNeuron 67, 199–212, July 29, 2010 ª2010 Elsevier Inc. 201
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Figure 3. Knockdown of MMP-10 and MMP-14 and Inhibitors of
MMP Activity Block Caspase Activation in Striatal Hdh111Q/111Q Cells
(A) Quantitative RT-PCR validation of MMP-10 and MMP-14 siRNA knock-
down. t test was performed (p = 0.0004 and p = 0.7E-9, respectively).
(B) Western blot analysis of siRNA targeting on expression of the indicated
MMP.
(C) Effect of siRNA to MMP-10, MMP-14 or nontargeting on activation of cas-
pase-3 inHdh111Q/111Q cells during 24 hr serumwithdrawal. Caspase activity is
in units dRFU/min/mg (ANOVA, n = 5, *p < 0.05 ***p < 0.001).
(D) Inhibition of MMPs with NNGH lowers caspase activation in striatal cells
(ANOVA analysis, p = 0.027 and 0.005).
(E) TIMP1 and TIMP3 overexpression of protein reduces caspase activation in
HD striatal cells (t test was performed, p = 0.3E-6 and 0.007).
The error bars represent standard deviation.
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202 Neuron 67, 199–212, July 29, 2010 ª2010 Elsevier Inc.assay, are not expressed in striatal cells. We used KLK cDNA
transfected Hdh111Q/111Q cells as a positive control to verify
KLK antibodies (data not shown).
These results suggest that enzymes that promote the produc-
tion of small N-terminal Htt cleavage products in our western
blotting assay are likely to modulate HD toxicity.
MMP-10 and MMP-14 Are Expressed in Striatal
Hdh111Q/111Q Cells
Since three of the nine validated hits (MMP-10, MMP-14, MMP-
23B) are members of the matrix metalloproteinase family and
one (ITGA2B) interacts withMMP-2 (Choi et al., 2008b), we chose
to further characterize thepotential roleof this family of enzymes in
HD. Most zinc-containing metalloproteases contain a character-
istic HEXXH consensus sequence that coordinates to the zinc.
Matrixmetalloproteinasesareasubfamily of themetzincins,which
share theextendedzinc-bindingXEXXHXXGXXHconsensusmotif
and a conserved methionine adjacent to the catalytic zinc. MMPs
were discovered by their ability to ‘‘dissolve’’ collagen fibers in
tadpole skin. There are 25humanMMPs (FigureS2) that are struc-
turally related zinc- and calcium-dependent enzymes. Some are
activated intracellularly by furin proteases and many have been
implicated in cancer, stroke, and arthritis.
To further analyze the effect of MMP knockdown in striatal
cells, we evaluated whether these proteases were expressed
in Hdh111Q/111Q cells and if the knockdown occurred in response
to the siRNA.Western blotting forMMP-10 andMMP-14 demon-
strated that they are present in Hdh111Q/111Q cells at detectable
levels, and introduction of siRNAs specific to their messenger
RNAs does cause a significant reduction in MMP mRNA and
protein expression (Figures 3A and 3B). We found the level of
knockdown correlated with the reduction in caspase activity as
titration of siRNA to MMP-10 (or deconvoluted siRNA pools)
further reduced protein levels correlating with a reduced cas-
pase-3 activity (data not shown). As shown in Figure 3C, siRNA
directed against MMP-10 or MMP-14 significantly reduced
caspase activation in Hdh111Q/111Q cells. We also found that
MMP-23B was knocked down by the siRNA treatment and
reduced caspase activation in Hdh111Q/111Q cells (data not
shown). TheMMP-23BmRNA level of expression inmouse stria-
tal cells and tissue is quite low when compared to MMP-14
(0.00663 ± 0.001 versus 0.5304 ± 0.006; 0.00026 ± 0.00006
versus 0.0078 ± 0.0003).
Next, we tested a pharmacologic inhibitor, NNGH, which is
a nonpeptidic, potent inhibitor of MMPs. The crystal structure
of the catalytic domain of human matrix metalloproteinase 10
has been solved with this molecule (Bertini et al., 2004). In addi-
tion to pharmacologic inhibitors, we tested known endogenous
inhibitors of MMPs-TIMP1 and TIMP3 in Hdh111Q/111Q cells. As
shown in Figures 3D and 3E, we found that these inhibitors
blocked Htt-mediated toxicity in Hdh111Q/111Q cells.
MMP-10 Is Processed in Striatal Hdh111Q/111Q Cells
and MMP Activity Is Increased
Given the involvement of MMPs in blocking Htt-mediated
toxicity, we investigated whether these proteins were processed
to their active forms in striatal cells containing mutant Htt. Strik-
ingly, we found in striatal Hdh111Q/111Q cells cultured with serum,
Figure 4. Activation of MMP in Striatal Hdh111Q/111Q Cells Relative
to Hdh7Q/7Q
(A) Striatal cells were electroporated with the indicated construct and cell
lysates were analyzed by western blotting with the indicated MMP antibody.
Cells were cultured in the presence of serum.
(B) Western blotting of striatal cell lysates probed with MMP antibodies.
(C) Activity of MMP fluorogenic substrate Mca-Pro-Leu-Dpa-Ala-Arg-NH2
(Mca = (7-methoxycoumarin-4-yl)-acetyl; Dpa = N-3(2,3-dinitrophenyl)-L-a-
b-diaminopropionyl) in striatal Hdh7Q/7Q and Hdh111Q/111Q cell lysates. The
activity is expressed in RFU/mg protein (n = 5, t test, **p < 0.01).
The error bars represent standard deviation.
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to Hdh7Q/7Q (Figure 4A). Further, MMP-10 was processed sug-
gesting activation of the protease in the striatalHdh111Q/111Q cells
as analyzed by western blotting (Figure 4A; 5.7-fold increase in
active form in Hdh111Q/111Q versus Hdh7Q/7Q cells, **p < 0.01).
The specificity of the MMP antibodies was confirmed by over-
expressing MMP-10 and MMP-14 in striatal cells (Figure 4B).
MMP-23B levels did not change in striatal Hdh111Q/111Q cells
when compared to Hdh7Q/7Q (data not shown).
The proteolytic processing of MMP-10 does not necessarily
indicate that levels of active MMP have increased in the mutant
Htt cells. We therefore evaluated the MMP activity in striatal
Hdh7Q/7Q and Hdh111Q/111Q cells. Figure 4C shows that MMP
enzymatic activity is significantly increased in striatal
Hdh111Q/111Q cells when compared to Hdh7Q/7Q using a fluoro-
genic substrate assay.
MMPs Are Activated in the R6/2 and YAC128 Mouse
Model of HD
Wenext examinedwhether our cell culture results could be reca-
pitulated in mouse models of the disease. We used a full-length
Htt (YAC128) and a fragmentmousemodel (R6/2) of HD. The full-
length HD model provides information about the natural history
of proteolysis of full-length Htt and the proteases activated.
The fragment model can provide information about the amplifi-
cation and feedback of proteases once a relevant fragment is
formed. The MMP enzymatic activity was assayed in the subre-
gions of the brain in the YAC128 and R6/2 mouse model of HD.
Figure 5A shows that MMP enzymatic activity is indeed
increased in 16-month-old YAC128 or 10-week-old R6/2
striatum, with a 1.6- to 1.8-fold increase in MMP activity relative
to the control striatum. We also examined the MMP enzymatic
activity in another polyQ disease, SCA7 (Mookerjee et al.,
2009). As shown in Figure 5A (right panel), MMP enzymatic
activity does not increase in SCA7 mice expressing ataxin-7-
92Q. This suggests MMP activation is relevant in HD but may
not be a feature of other polyQ diseases.
We used zymography to analyze the specific activity of the
various MMPs in HD mouse brain, after MMP affinity precipita-
tion (using gelatin beads). As shown in Figure 5B, we found
elevated MMP activity detected in several bands ranging from
50 kDa to 90 kDa in lysates of the cortex and striatum of
R6/2 mouse when compared to controls. The most robust
increase in R6/2 lysate activity corresponds to the 50 kDa
bands (Figure 5B). Since MMP-10 migrates at around 50 kDa
in its active form, this result is in agreement with our striatal
cell line studies. We cannot exclude the possibility that other
co-migrating MMPs may contribute to the observed activity.
The band at 90 kDa may represent MMP-9 (MW 92 kDa, arrow-
head), a protease activated by MMP-10.
In Situ Gelatinase Activity
Since the MMP activity assay and zymography indicated
increased levels of MMP activity in R6/2 and YAC128 lysates,
we employed an in situ gelatinase assay to evaluate the levels of
MMP directly in R6/2 and control tissue sections. In sections
from R6/2 mice, we observed increased fluorescence when
compared to control in both the striatum and cortex (Figure 5C).Inhibition with the MMP inhibitor 1,10-phenanthroline abolished
the fluorescence signal, confirming that the activity was attribut-
able to MMPs (Figure S3). Since MMP family members can be
expressed in both glial and neuronal populations, we determinedNeuron 67, 199–212, July 29, 2010 ª2010 Elsevier Inc. 203
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Figure 5. MMP Activity Is Elevated in YAC128 and
R6/2 Striatal Tissue but Not in a Spinocerebellar
Ataxin-7 polyQ Mouse Model
(A) MMP activity assay with fluorogenic substrate activity
measured in units of RFU/mg protein (t test, n = 3,
*p < 0.05).
(B) Striatal and cortex tissue immunoprecipitates using
gelatin Sepharose 4B beads were resolved on a 10%
zymogram gelatin gel and assayed for gelatinase activity.
Arrowhead indicates 90 kDa activity.
(C) In situ zymography on 12–13 week control and R6/2
mouse brain tissue. MMP enzyme activity shown by
a DG gelatin fluorescein conjugate MMP substrate.
Images are shown at 203 magnification.
The error bars represent standard deviation. See also
Figure S3.
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Matrix Metalloproteinases Modify Huntingtinthe subpopulation that containedMMP activity by costaining with
GFAP (glial specific) or NeuN (neuronal specific). The majority of
MMP staining is present in neurons, although some MMP activity
does colabel GFAP-positive cells (Figure S3).
Direct versus Indirect Effects of MMPs on HD-Mediated
Toxicity
Knockdown of MMPs suppresses mutant Htt toxicity and
decreases the amount of small Htt fragment accumulation. This
indicates that MMPs may either cleave mutant Htt directly or
modulate events upstream or downstream of Htt cleavage. For
example, in HIV, MMP-2 cleaves stromal cell-derived factor
(SDF)-1a to activate neuronal cell death (Vergote et al., 2006).
To determine whether Htt is a direct substrate for MMP-10 or
MMP-14, we incubated cell lysates expressing Htt with the
recombinant MMPs. As a control, we included MMP-2, an
MMP family member not found to alter HD cellular toxicity or
proteolysis in our original screen. As shown in Figure 6A,204 Neuron 67, 199–212, July 29, 2010 ª2010 Elsevier Inc.full-length wild-type or mutant Htt expressed in
cellular lysates is a substrate for MMP-10, but
not MMP-14 or MMP-2. A cleavage product
appears at 48 kDa originating from normal Htt,
and 70 kDa for mutant Htt148Q. In vitro transla-
tion of Htt15Q (1-1212) also confirmed that Htt
is a substrate for MMP-10 but not MMP-14 or
MMP-2 (Figure 6B). All three MMP family
members were equally active against the fluo-
rescent substrate, Mca-Pro-Leu-Dpa-Ala-Arg-
NH2, suggesting that Htt is a preferred substrate
for MMP-10 (data not shown). These data indi-
cate that MMP-10 knockdown suppresses
Htt toxicity through its direct effect on Htt
cleavage while the effect of MMP-14 knock-
down is indirect.
MMP-10 Cleaves Htt at Amino Acid 402
MMP-10 appears to cleave Htt in a region closer
to the N terminus than the caspase and calpain
cleavage products (55–72 kDa) (Gafni et al.,
2004; Hermel et al., 2004; Wellington et al.,
1998) producing a smaller 48 kDa product.Recent in vitro studies suggest Htt is also cleaved at amino
acid 167 (Ratovitski et al., 2009). Deletion of the residues at
this site has no effect on the proteolysis of Htt by MMP-10
(Figure 6B). Therefore, the site of MMP-10 cleavage is likely
between amino acid 167 (Cp2 site) and 469 (calpain site).
Consistent with this, Htt (1-450) is still a substrate for MMP-10
(Figure 6C).
To locate the approximate site of cleavage, Htt15Q (1-469)
and Htt138Q (1-469) were in vitro translated and incubated
with MMP-10. As shown in Figure 6D, MMP-10 addition to
Htt15Q (1-469) and Htt138Q (1-469) generates a 48 kDa and
70 kDa fragment, respectively. Htt15Q (1-167), Htt15Q (1-329),
Htt15Q (1-378), Htt15Q (1-414), and Htt138Q (1-167) serve as
size controls. Analysis of the molecular mass of the Htt15Q
cleavage product suggests cleavage occurs around amino
acid 414 of Htt. Examination of the amino acid sequence of Htt
in this region, and comparison to known MMP substrates,
suggests a possible cleavage site at amino acid 402. To test
A B C
D E F
G
Figure 6. MMP10 Directly Cleaves Htt
(A) Full-length Htt23Q and Htt148Q cellular 293T lysates (with protease inhibitors) were treated with recombinant MMP-2, MMP-10, or MMP-14 and western blot
was probed with Htt N-terminal antibody.
(B) In vitro translated Htt15Q (1-1212) and Htt15Q (1-1212) D167–170 mutants were treated with recombinant MMP-2, MMP-10, or MMP-14. A Htt cleavage
product of 45 kDa appears when MMP-10 is added and is not affected by deletion of amino acids 167–170.
(C) Htt23Q (1-450) andHtt57Q (1-450) cellular lysates were treatedwith recombinant MMP-10 andwestern blot was probedwith anti-6HisGS (tag at N terminus of
Htt).
(D) In vitro translation of Htt15Q (1-469), Htt15Q (1-414), and Htt15Q (1-378) demonstrates that cleavage occurs between amino acids 378 and 414.
(E) In vitro translation of a Htt15Q (1-469) deletion mutant (D402-403 or DGI) reduces the MMP-10 product.
(F) Control and HD postmortem tissue lysates from caudate were analyzed bywestern blotting. Blots were probedwith anti-huntingtin 115–129 antibody. The size
of the fragment is similar to that generated by MMP-10 treatment of HD lysates (with protease inhibitors) shown in lane 3 and 4. TBP was utilized as a loading
control.
(G) Immunofluorescence of striatal Hdh111Q/111Q cells labeled with anti-huntingtin 115–129 antibody (green) and anti-MMP-10 antibody (red). Left panel cultured
in serum; right cultured in serum-free media. Cells are shown at 1263 magnification and arrows indicate cell analyzed and colocalization. Arrowheads point to
MMP-10 colocalization. Quantitative analysis of immunofluorescence via Imaris software indicates significant colocalization in cells as shown in right panel (t test,
**p < 0.01).
The error bars represent standard deviation. See also Figure S4.
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shown in Figure 6E, deletion of amino acids 402–403 (DGI) of
Htt results in a protein resistant to proteolysis by MMP-10.
Htt15Q (1-414), Htt15Q (1-402) and Htt15Q (1-378) serve assize controls. Htt15Q (1-402) matches the molecular mass of
the MMP-10-generated Htt cleavage product.
To confirm that the cleavage product is generated in vivo, HD
post-mortem cellular lysate were compared to control lysate andNeuron 67, 199–212, July 29, 2010 ª2010 Elsevier Inc. 205
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Matrix Metalloproteinases Modify Huntingtinanalyzed by western blotting. As shown in Figure 6F, a Htt
cleavage product around 45–55 kDa is evident in the HD tissue
and is consistent with the size of the products in our in vitro
assays (accounting for a CAG repeat in the patient of 42).
Consistent with this, when we treated HD postmortem cellular
lysates with MMP-10 a cleavage product increased at 50 kDa
(Figure 6F). Further, recent analysis of the HD150 knockin mice
suggests Htt fragments of this size are present in striatal and
cortical lysates (Landles et al., 2010).
Since Htt is likely to be a substrate via intracellular cleavage by
MMP-10, we evaluated localization of endogenous Htt and
MMP-10. As shown in Figure 6G, Htt and MMP-10 colocalize
in discrete punctate structures (left panel). Further, in cells
undergoing cell death Htt and MMP-10 show enhanced colocal-
ization (right panel). Quantification of colocalization is shown in
the bar graph of Figure 6G. The colocalization does not result
from a direct protein-protein interaction as we did not find
MMP-10 and Htt coimmunoprecipitate (Figure S4).
Reduced Activities of MMP and Other Proteases
Identified in the siRNA Screens Improve Neuronal
Function in a Drosophila Model of HD
The data presented above suggest that reducing the activity
of MMPs, and perhaps other proteases, may ameliorate Htt-
induced neuronal dysfunction in vivo. To test this idea, we
used a behavioral readout in a HD Drosophilamodel expressing
the first 336 amino acids of the human protein including 128
glutamines in exon 1. In this model system, neuron-specific
expression of expanded Htt leads to quantifiable progressive
motor deficits (Kaltenbach et al., 2007). In contrast to the
mammalian genome that contains 25 MMPs with partially over-
lapping functions, Drosophila only has two MMP family
members, Dm1-MMP and Dm2-MMP. Although there are no
clear orthologous relationships between the Drosophila and
mammalian genes, they are clearly evolutionarily conserved as
evidenced by their domain structure, amino acid sequence
similarities, and functional interactions (Llano et al., 2000;
Page-McCaw, 2003, 2008; Wei et al., 2003). Of the two
Drosophila genes Dm2-MMP is expressed in the postembryonic
brain (Page-McCaw et al., 2003), while Dm1-MMP expression
was not detected in the adult (Llano et al., 2000). Thus, we asked
whether genetically reducing the activity of Dm2-MMP leads to
improvement of Htt-induced motor dysfunction. We found that
heterozygous loss-of-function alleles of Dm2-MMP show robust
and significant effects in improving themotor performance of HD
flies. Importantly, this observation was reproduced with two
different Dm2-MMP alleles indicating that the effect is caused
by reduced function of Dm2-MMP, and not by genetic back-
ground effects (Figures 7A, 7I, and 7J). Figure 7 shows as well
that partial loss of function in Drosophila homologs of CAPN5,
CAPN7, IMP5, and RNF128 also ameliorate motor deficits in
the HD Drosophila model. These data support the idea that
MMPs and perhaps other proteases characterized here may
be therapeutic targets in HD.
In addition to the behavioral readout, we also tested for photo-
receptor degeneration in these flies (Figure S5). Expression of
NT-Htt[128Q] in the eye causes severe photoreceptor degener-
ation, tissue loss and significant shortening in the thickness of206 Neuron 67, 199–212, July 29, 2010 ª2010 Elsevier Inc.the retina when compared to controls (Figure S5). Animals
expressing NT-Htt[128Q] and with decreased levels of CalpA,
Sol, and Dm2-MMP showed improved retinal integrity and
improved thickness when compared to animals expressing
NT-Htt[128Q] alone.
DISCUSSION
We have carried out an unbiased RNAi screen to identify
proteases that when knocked down reduced the production of
toxic N-terminal Htt proteolytic fragments.We screened 514 siR-
NAs targeting all known and predicted human proteases and
found 11 proteases that altered the level of the smallest
N-terminal mutant Htt protein detected by the 1C2 anti-polyQ
antibody. The proteases identified include members of the
calpain family (CAPN5 and CAPN7); the signal peptide
protease-like IMP5 and an amino-terminal signal peptide
protease (SPC18); members of the secreted serine-protease
kallikrein family (KLK10 and KLK11); the transmembrane-E3-
ubiquitin ligase, RNF128; the MMP-2 interacting integrin,
ITGA2B (Choi et al., 2008b); and three members of the matrix
metalloproteinase family (MMP-10, MMP-14, MMP-23B).
Our results are consistent with the prior observations demon-
strating that calpain family members are involved in the
proteolysis of Htt and pathogenesis of HD (Gafni and Ellerby,
2002; Gafni et al., 2004; Kim et al., 2001). Both CAPN5 and
CAPN7 levels are increased in HDmouse models and post-mor-
tem tissue. Several other interesting proteases were identified in
our studies. For example, IMP5, a signal peptide peptidase (SPP)
is an unusual aspartyl protease that mediates clearance of signal
peptides by proteolysis within the endoplasmic reticulum (ER)
(Krawitz et al., 2005). Like presenilins, the proteolytically active
subunit of the gamma-secretase complex, SPP contains
a critical GXGD motif in its C-terminal catalytic center. Htt is
associated with the ER, and perhaps IMP5 plays a role in Htt
processing in this organelle (Atwal and Truant, 2008). Currently
the substrates andmechanism for these proteases are unknown.
Another identified protease, RNF128, is a ubiquitin E3 ligase, that
promotes proteasomal degradation via Lys-48 linkages by
capture of transmembrane substrates (Lineberry et al., 2008).
Further studies will be required to determine if Htt is a substrate
for RNF128 and how this enzyme alters proteolysis of Htt as
observed in our screen. Decreasing the levels of these four
proteases (CAPN5, CAPN7, IMP5, and RNF18) suppresses
Htt-induced toxicity in mouse striatal cells. Furthermore, knock-
down of their Drosophila homologs suppresses neuronal
dysfunction in a fly HD model. This underlines their potential as
therapeutic targets for HD.
Over 36%of the proteases identified in our screen werematrix
metalloproteinase family members, and therefore we focused
our analysis on these proteases in HD. In humans, there are
187 metalloproteases, and this represents the largest of the
five protease classes (Hornebeck and Lafuma, 1991; Malemud,
2006). There are 25 human MMPs and four TIMPs. MMPs are
traditionally thought to degrade the extracellular matrix, but
emerging technology suggests there are many other substrates
for MMPs such as chemokines, cell receptors, cyotokines,
growth factors and fas ligands. We found that the knockdown
Figure 7. Reduced Activity of Proteases Improves Motor Dysfunction in HD Drosophila Model
(A) Table summarizing the effects caused by modulating the levels of the indicated proteases on NT-Htt[128Q]-induced motor performance in Drosophila.
Columns 1 and 2 list the human proteases andDrosophila homologs; column 3 shows the amino acid sequence similarity as the blast E value; column 4 indicates
the specific allele tested; column 5 shows the allele class: inducible RNAi constructs (RNAi), loss of function caused by insertion of transposable element (LOF) or
overexpression caused by an activating transposable element (OE); column 6 reveals the suppressor (S) or enhancer (E) effect of each allele on NT-Htt[128Q]-
induced motor deficits.
(B–K) Quantification of motor performance as a function of age in flies of the indicated genotypes using a climbing assay. Control animals expressing just the
Elav-Gal4 driver perform well in the climbing assay beyond 14 days (control-blue dashed line). Flies expressing NT-Htt[128Q] in the nervous system either alone
or together with a control RNAi, show progressive motor dysfunction when compared with controls (NT-Htt[128Q] and NT-Htt[128Q]/UAS-whiteRNAi, respec-
tively. Black dashed lines). Flies expressing NT-Htt[128Q] in the nervous system but with decreased levels of the proteases: CalpA (CAPN5 homolog, B–C);
Sol (CAPN7 homolog, E); Spp (IMP5 homolog, F); CG17370 (IMP5 homolog, G–H); Dm2-MMP (MMP homolog, I–J) or Gol (RNF18 homolog, K) show improved
motor performance (red solid line in Band C and E–H). In contrast, flies expressing NT-Htt[128Q] with increased levels of the protease Sol (CAPN7 homolog)
display a worse motor performance (red solid line in D). Data was analyzed using ANOVA followed by Tukey’s hsd. Error bars represent SEM. *p < 0.01,
**p < 0.001, ***p < 0.0001. Flies were raised at 26.5C.
See also Figure S5.
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Matrix Metalloproteinases Modify Huntingtinof theMMP-2 interacting integrin ITGA2B (Choi et al., 2008b) and
three members of the matrix metalloproteinase family (MMP-10,
MMP-14, MMP-23) suppressed toxicity in an immortalized stria-
tal cell line harboring a knock-in of mutant Htt. We show that
MMP activity is increased in cell culture and animal models of
HD. Furthermore, MMP-10 is proteolytically processed and
activated in these models. Relevant to our studies, MMP-10 isknown to be upregulated in stroke and is present in neurons
(Cuadrado et al., 2009).
The mechanism by which MMPs suppress HD-mediated
toxicity could be through the known function of MMPs in
targeting the extracellular matrix or cytokines (see Figure 8 for
potential mechanisms). However, our screen was designed to
identify proteases that when knocked down would reduce theNeuron 67, 199–212, July 29, 2010 ª2010 Elsevier Inc. 207
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Figure 8. Model of PossibleMechanisms for
Neurotoxicity of MMPs in Huntington’s
Disease
In HD striatal cells, MMP-10 and MMP-14 are acti-
vated. Upon activation, MMPs may cause neuro-
toxicity at different cellular locations/substrates
in our model. Htt may be processed directly or
indirectly by MMPs (through activation of other
proteases). In striatal neurons, MMP-10 may pro-
cessmutant Htt into a toxic fragment intracellularly
and possibly processing other cellular substates.
Proteolysis of these substrates would activate
cell death. On the outside of the cell (MMP is mem-
brane bound or secreted), proteolysis of extracel-
lular substrates could result in processing of
substrates involved in inflammation. This could
also occur in glia as depicted in our model.
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Matrix Metalloproteinases Modify Huntingtinproteolysis of mutant Htt. In order to determine the mechanism
for MMPs in HD, we evaluated whether Htt is a substrate for
particular MMP familymembers.We found thatMMP-10 cleaves
Htt directly whereas MMP-14 and MMP-2 do not. Inhibition of
MMP-10 by siRNA-mediated knockdown reduces the genera-
tion of the smallest detectable N-terminal polyQ-containing
fragment of Htt in cell culture. We mapped the cleavage site of
Htt generated by MMP-10 to amino acid 402. It is noteworthy
that the MMP-10 cleavage site in Htt is highly conserved, with
(S/T)XXGG(I/L) being present from human to Fugu. These results
suggest that knockdown of MMP-10 reduces HD toxicity
through directly effecting the proteolysis of Htt. For the other
MMP family members, known mechanisms of cleavage of
extracellular matrix or cytokines is likely to play a significant
role in reducing HD-mediated toxicity.
Recent evidence suggests that some matrix metalloprotei-
nase family members such as MMP-3 function inside the cell
during neuronal cell death (Choi et al., 2008a). While MMPs are
generally thought to be secreted as proenzymes and processed
to their active forms outside the cell, we found that MMP-10 was
activated inside the cell. This has been reported for other MMPs
(Luo et al., 2002; Pei and Weiss, 1995, 1996). Furthermore, we
found that MMP-10 and Htt colocalize, suggesting the possibility
that cleavage occurs intracellularly. Htt is known to associate
withmembranes and has a site of palmitoylation that would allow
proteolysis to occur at the membrane surface (Kegel et al.,
2009a, 2009b; Yanai et al., 2006).
Activation of MMPs is known to occur in diseases including
stroke, cancer and HIV (Malemud, 2006). In our study, we found208 Neuron 67, 199–212, July 29, 2010 ª2010 Elsevier Inc.MMPs to be activated in cellular and
animal HD models. Knockdown of par-
ticular MMP family members reduced
mutant Htt-mediated cell death in an
immortalized striatal cell line and signifi-
cantly improved motor deficits caused by
neuronal expression of polyQ-expanded
Htt in Drosophila. These data suggest
that selective inhibition of the implicated
MMP family members should be consid-
ered for developing novel therapeuticsfor HD. For example, MMP-9 knockout mice show improved
outcomes after cerebral ischemia (Asahi et al., 2000). This may
be directly relevant to HD as a recent analysis of postmortem
HD revealed MMP-9 is upregulated in HD brain and absent in
age-matched controls (Silvestroni et al., 2009). AG3340 (prino-
mastat), a small molecule hydroxamate-based inhibitor of
MMPs, was examined in a model of chronic cerebral hypoperfu-
sion and is neuroprotective in adult rats and mice when adminis-
tered just before insult (Cai et al., 2006). Reduced activation of
astrocytes and microglia was also associated with retained
blood-brain barrier integrity in these studies. In addition, in
a mouse model of middle cerebral artery occlusion, the gelati-
nase-selective compound SB-3CT reduced infarct volume
when administered starting at either 2 or 6 hr after insult (Gu
et al., 2005).
Taken together, our results suggest that general inhibition of
MMPs may be of therapeutic benefit in Huntington’s disease
and that specific inhibitors of MMP-10 may be particularly
relevant to disease treatment.
EXPERIMENTAL PROCEDURES
Plasmid Constructs
The full-length expanded polyQ Htt expression construct, Htt138Q, and
pcDNA 3.1 (Invitrogen), were used for the western blotting screen (Martindale
et al., 1998). For evaluatingMMP proteolysis of Htt with recombinant enzymes,
human Htt constructs expressing the first 469, 414, 402, 378, 329, and 167
amino acids were made by site-directed mutagenesis of the Htt 15Q and
138Q (1-1212) constructs (Wellington et al., 2000). Amino acids 167 to 170
were deleted in Htt 15Q (1-1212) and 402 to 403 were deleted in Htt 15Q
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Matrix Metalloproteinases Modify Huntingtin(1-469) to help map the MMP cleavage site. Primers for the 469 stop construct
were F, 50-CAGCAGCTCTGCCTTAACATAGTCAGTGAAGGATGAGATC-30,
and R, 50-GATCTCATCCTTCAC TGACTATGTTAAGGCAGAGCTGCTG-30;
414 stop construct were F, 50-GCTAAGGAGGA GTCTGGTTGACGAAGCCGT
AGTGGGAG-30, and R, 50-CTCCCACTACGGCTTCGTC AACCAGACTCC
TCCTTAGC-30; 402 stop construct were F, 50-CTGACCGCAGTCGGGG
GCTAGGGGCAGCTCACCGCTGCTAAG-30, and R, 50-CTTAGCAGCGGTGA
GCTGCCCCTAGCC CCCGACTGCGGTCAG-30; 378 stop construct were
F, 50-CAATGTTGTGACCGGAGCCTAGGAG CTGTTGCAGCAGCTC-30, and
R, 50-GAGCTGCTGCAACAGCTCC-TAGGCTCCGGTCACAACATTG-30; 329
stop construct were F, 50-GGTGCCCTTGCTGCAGCAGTAGGTCAAGGACAC
AAGCCTG-30, and R, 50-CAGGCTTGTGTCCTTGACCTACTGCTGCAGCAAG
GGCACC-30; 167 stop construct were F, 50-GATTCTAATCTTCCAAGGTAGC
AGCTCGAGCTCTATAAGG-30, and R: 50-CCTTAT AGAGCTCGAGCT-GCT
ACCTTGGAAGATTAGAATC-30; D167–170 were F, 50-CAAAGCTTTGATGG
A-TTCTAATCTTCCAGAGCTCTATAAGG-30, and R, 50-CCTTATAGAGCT
CTGG-AAGATTAGAATCCATCAAAGCTTTG-30; and D402–403 were F,
50-ccctgaccgcagt cggcggccagctcaccgctgctaaggag-30, and R, 50-CTCCTTAG
CAGCGGTGAGCTG GCCGCCGACTGCGGTCAGGG-30. Polymerase chain
reactions used 100 ng of DNA, 5.0 ml of 103 Pfu buffer (Stratagene), 0.2 mM
dNTPs (Promega), 125 ng each of forward and reverse primers (Integrated
DNA Technologies), 5% Me2SO, and 1 ml Pfu polymerase (Stratagene) for
18 cycles at 96C for 1 min, 55C for 1 min, and 68C for 24 min, then 68C
for 7 min. Plasmids were DpnI (Promega)-treated, transformed into XL1-Blue
supercompetent cells (Stratagene), and purified using the QIAprep Spin Mini-
prep Kit (QIAGEN). Mutations and CAG length were confirmed by DNA
sequencing. Constructs containing 6his-Htt23Q (1-450) and 6his-Htt55Q
(1-450) were used for western analysis (Kaltenbach et al., 2007).
Htt Proteolysis Western Blot Primary Screen
We screened Dharmacon’s siGENOME SMARTPOOL Protease Set consisting
of 514 protease siRNA pools of four duplexes for their ability to reduce the
abundance of a mutant Htt N-terminal fragment. Human embryonic kidney
293T (HEK293T) cells were cultured in Dulbecco’s modified eagle medium
(DMEM; Mediatech) containing penicillin/streptomycin (100 units/ml/
100 mg/ml) and 10% heat-inactivated fetal bovine serum (FBS) (GIBCO). Cells
were seeded in DMEM with 10% serum without penicillin/streptomycin at 53
104 cells/well in collagen-coated 96-well plates (BD, Biocoat) and incubated at
37C for 24 hr. Lipofectamine 2000 (Invitrogen) was used for transient transfec-
tions according to manufacturer’s instructions. Cells were transfected with
80 ng of DsRed DNA, 0.32 mg pcI-Htt138Q DNA, 136 nM siRNA and 1 mg Lip-
ofectamine 2000 in 25 ml DMEM lacking serum or penicillin/streptomycin. After
a 48 hr incubation at 37C, media was replaced with DMEM containing 10%
FBS and 1 mM epoxomicin and incubated for an additional 24 hr. Cells were
lysed directly in wells with 25 ml M-PER (Thermo Scientific) containing protease
inhibitors (1 tablet/10 ml, Complete Mini, EDTA-free, Roche) and RQ1 DNase
(Promega) and 1mMMgCl2. Plateswere shaken at 700 rpm for 10min. To 10 ml
of lysate, 6 ml of 43 LDS loading buffer (Invitrogen) and 1 ml of 1M DTT was
added and heated to 99C for 5 min. Lysate proteins were resolved on 4%–
12% bis-tris gels, transferred to nitrocellulose membrane, and probed with
monoclonal antibody MAB1574 (1C2, 1:2000, Chemicon). Multiple film expo-
sures were collected for each blot, and nonsaturated films were scanned and
analyzed by densitometry using ImageQuant TL. Hits were identified as those
siRNAs which reduced the amount of the55 kDa band (relative to the FL Htt)
by 30% or more in duplicate. The 41 siRNAs that met these criteria were then
retested in triplicate.
Secondary Screen for Caspase 3/7 Activity Suppression in Striatal
Hdh7Q/7Q and Hdh111Q/111Q Cells
Striatal cell lines cells were nucleofected with siRNA as described below,
plated at 5 3 104 cells/well on collagen-coated 96-well plates, and incubated
for 48 hr in DMEM containing 10% FBS and 100U/ml/100 mg/ml penicillin/
streptomycin, followed by serum-deprivation for 24 hr before assaying. Cells
were lysed in 50 ml of a 50/50 mixture of DMEM/Apo Lysis Buffer (Cell Tech-
nology Inc). Aliquots (10 ml) were taken for protein quantification by the BCA
method (Pierce) before the addition of DMEM/Apo Lysis Buffer with 20 mM
DTT and 2% APO 3/7 HTS Substrate (Cell Technology, Inc.). The substrateis a fluorescence-quenched Rhodamine-DEVD conjugate ((zDEVD)2-Rhoda-
mine 110) that fluoresces (Ex485nm/Em530nm) upon cleavage of DEVD by
caspase 3/7. Fluorescence was read for 1 hr at 37C using a Fusion-Alpha
FP HT (PerkinElmer). Toxicity is represented as caspase 3/7 activity in
dRFU/min/mg protein.
Western Blotting of Striatal Hdh7Q/7Q and Hdh111Q/111Q using siRNA
Directed against Target Proteases
Dharmacon siGENOME SMARTpools (Thermo Scientific) were used for siRNA
disruption of CASP3 (M-043042), CAPN5 (M-042053), CAPN7 (M-043031),
IMP5 (M-054596), ITGA2B (M-046584), KLK10 (M-062688), KLK11
(M-043814), MMP-10 (M-049762), MMP-14 (M-062241), MMP-23 (M-
047760), RNF128 (M-060871), SPC18 (M-056742), and nontargeting (D-
001206). Striatal Hdh7Q/7Q and Hdh111Q/111Q cells were maintained at 33C
in a humidified atmosphere of 95% air and 5% CO2, in DMEM containing
10% FBS, 100 U/ml penicillin and 100 mg/ml streptomycin. RNAi treatment
of cells was as follows: 1 3 106 cells per siRNA treatment were collected
and nucleofected using Kit L (Amaxa) with 3 mg of siRNA, and then 6 3 105
cells/well were plated on 6-well plates. After 48 hr incubation, cells were serum
starved for 24 hr followed by harvesting for analysis by western blotting.
For western blotting without siRNAs the cells were treated with and without
serum.
Cells were resuspended in M-PER with protease inhibitors (1 tablet/10 ml,
Complete Mini, EDTA-free, Roche). Whole-cell lysates were sonicated 5 3
5 s pulses at 40 mA. Samples were centrifuged at 22K rpm and supernatant
was collected for western blotting. 43 LDS sample buffer (Invitrogen) and
1 ml of 1M DTT were added to 20–40 mg total protein and boiled for 10 min.
Samples were resolved by SDS-PAGE using 4%–12% NuPage Bis-Tris gels
under reducing conditions in MES running buffer. Gels were run at a constant
200V for 1 hr, transferred to 0.45 mm nitrocellulose membranes in 13 NuPage
transfer buffer for 8 hr at 20V. Membranes were incubated in TBS with 0.1%
Tween 20 (TBS-T), 5% non-fat milk for 1 hr. Primary antibodies anti-MMP-
10 (1:5000, Abcam ab28205), MMP-14 (1:2000, Abcam ab51074), MMP-23
(1: 500, Abcam ab5314); anti-polyQ (1:2000, Chemicon, MAB1574); and
anti-Htt (1:500, MAB2166; 1:1000, MAB5490; 1:1000, MAB5492; 1:100
MAB5374, all from Chemicon); anti-tubulin (1:1000, Sigma); and anti-b-actin
(1:1000, Cell Signaling) were diluted into TBS with 0.1% Tween 20 (TBS-T),
5% non-fat milk for 1 hr. Blots were developed using Pierce ECL (Thermo
Scientific). Band intensity was quantified using ImageQuant TL v2005.
RT-PCR of Striatal Cell Knockdown and Mouse Tissue mRNA
Total RNA was isolated from electroporated striatal cells (1 well of a 6-well
plate) or striatal mouse tissue with the RNeasy Mini Kit (QIAGEN) according
to the manufacturer’s instructions. One microgram of RNA was converted to
cDNA by using the Message Sensor RT kit (Applied Biosystems). Real-time
quantitative PCR (qPCR) was performed with either Universal Probe Library
dye (UPL from Roche) or SYBR Green (Applied Biosystems) on the LightCycler
480 system (Roche). For quantification the threshold cycle Cp of each ampli-
fication was determined by the second derivative analysis provided by the
LightCycler 480 software and the 2-DDCp method was used to determine the
relative expression level of each gene normalized against the house-keeping
gene b-actin. The specificity of each pair of primers was tested by comparing
to a negative control sample of water on both quantification analysis and high
resolution melting curve analysis. The primers used are as follows: MMP10 F,
50-ATGTTCTGTGGCTCCGGATGAG-30, R, 50-TGTGCTCAGGTGATGCTTT
GTG-30; MMP14 F, 50-AACTTCGTGTTGCCTGATGA-30, R, 50-TTTGTGGG
TGACCCTGACTT-30; MMP23 F, 50-GCACTGTCCCAGGATGAACT-30, R, 50-C
CCAGGATGCACACACAA-30.
MMP Cell Activity Assays
Striatal Hdh7Q/7Q and Hdh111Q/111Q cell pellets or mouse striatal tissue were
lysed in M-PER or T-PER (Thermo Scientific), respectively. MMP enzyme
activitywasmeasuredusing theMMPassay kit (Biomol) per themanufacturer’s
protocol with the fluorogenic substrateMca-Pro-Leu-Dpa-Ala-Arg-NH2 (Mca=
(7-methoxycoumarin-4-yl)-acetyl; Dpa = N-3(2,3-dinitrophenyl)-L-a-b-diami-
nopropionyl). Fluorescence was normalized to total protein in the lysate.Neuron 67, 199–212, July 29, 2010 ª2010 Elsevier Inc. 209
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Gelatinase activity from cortex and striatum of R6/2 and control mouse tissue
lysates (T-PER) was measured following affinity purification. Briefly, 500 mg of
total protein was added to 500 ml lysis buffer (50 mMTris-HCl [pH 7.6], 150mM
NaCl, 5 mM CaCl2, 0.05% Brij-35, 1% Triton X-100, and 0.02% NaN3) and
affinity purified over gelatin Sepharose (GE Healthcare). MMP protein was
eluted with 10% DMSO in PBS. One hundred fifty micrograms of purified
lysate was added to three microliters of 63 SDS buffer and resolved on
a 10% zymogram gel (Invitrogen) containing 0.1% gelatin. Following electro-
phoresis, gels were incubated in 2.7% Triton X-100 at room temperature for
30 min then placed in developing buffer, 50 mM Tris-HCl (pH 7.6), 200 mM
NaCl, 5 mM CaCl2, and 0.05% Brij-35, for 72 hr at 37
C. After developing,
gels were stained in SimplyBlue (Invitrogen) for 1 hr at room temperature
and destained in ddH2O overnight. Gelatinase activity was detected as a
clearing of the blue-stained gelatin. Mouse tissue was collected in accordance
protocols approved by IACUC.In Situ Zymography, Immunohistochemistry of R6/2, and Control
Brain Sections
R6/2 and control mice were perfused with ice cold PBS (pH 7.4), and brain
tissue was collected and immediately frozen on dry ice. Frozen 20 mm sagittal
sections were mounted on slides and quickly exposed to zymography solution
of pH 7.4 containing 50 mM Tris-HCL, 150 mM NaCl, 5 mM CaCl2, 0.3 mM
NaN3, and 40 mg DQ gelatin (Molecular Probes, Eugene, OR) overnight at
37C. Control slides included 1 mM 1-10-phenanthroline MMP inhibitor. Reac-
tion products were visualized on a confocal microscope (LSM510, Zeiss).
In situ zymography sections were fixed in 4% PFA in PBS, permeabilized in
1%Tween in 13 TBS, blocked in 10%normal donkey serumwith chicken anti-
mouse IgG at 1:500. Primary antibodies were diluted in 1%BSA in 13 TBS and
incubated 24 hr at 4C. All washeswere done 33 10min in 1X TBS. Secondary
antibody was diluted in 1% BSA in 13 TBS and applied to slices for 1 hr.
MAB5374 Htt(82-150) antibody (1:50, Chemicon) was labeled with Alexa 647
donkey anti-mouse (Molecular Probes); and GFAP (1:500, Sigma) was labeled
with Alexa 555 donkey anti-rabbit (Molecular Probes). Following incubation in
secondary antibody, slices were washed and mounted in Prolong Gold (Invi-
trogen) with DAPI.In Vitro Protein Synthesis and Cleavage
Htt15Q (1-1212), Htt15Q (1-469), Htt138Q (1-469), Htt 15Q (1-414), Htt 15Q (1-
402), Htt 15Q (1-378), Htt 15Q (1-329), Htt15Q (1-167), Htt138Q (1-167),
Htt15Q (1-1212) D167–170 and Htt 15Q(1-469) D402–403 constructs were
translatedwith TNTCoupled Reticulocyte Lysate Systems kit (Promega). Three
microliters of translation product was diluted in M-PER and 10 U of the cata-
lytic domain of MMP-2, MMP-10, or MMP-14 (Biomol) were added and incu-
bated for 2 hr at 37C. Following addition of SDS and DTT, samples were
heated to 90C for 10 min and run on 12% Bis-Tris gels. Gels were fixed
and dried before exposing to film.Immunocytochemistry of Striatal Hdh111Q/111Q Cells
Immunocytochemistry was performed on Hdh111Q/111Q cells cultured with
serum or 24 hr serum depravation. Cells were fixed in 4% PFA in PBS for
20 min and washed 5 min in 13 PBS and 23 5 min in 13 TBS. Blocking,
primary antibodies, secondary antibodies, and washes were applied accord-
ing to in situ procedure described above. MAB5490 antibody Htt (115-129)
(1:500, Chemicon) was labeled with Alexa 555 donkey anti-mouse (Molecular
Probes) and MMP10 antibody (1:2000, Abcam) was labeled with Alexa 488
donkey anti-rabbit. Cells were washed 3 3 5 min in 13 TBS and mounted in
Prolong Gold (Invitrogen) with DAPI.Drosophila Motor Performance Assay
Strains were obtained from either the Bloomington Stock Center (http://
flystocks.bio.indiana.edu) or the Vienna Drosophila RNAi Center (http://
stockcenter.vdrc.at/control/main). Motor performance test are described in
the Supplemental Experimental Procedures.210 Neuron 67, 199–212, July 29, 2010 ª2010 Elsevier Inc.SUPPLEMENTAL INFORMATION
Supplemental Information includes five figures and Supplemental Experi-
mental Procedures and can be found with this article online at doi:10.1016/j.
neuron.2010.06.021.
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